A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects

An Open-label, 36-week Extension Study on Amdoxovir at 500 mg Bid or 300 mg Bid in Combination With Zidovudine and Lopinavir/Ritonavir in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01738555

Enrollment

Registered

2012-11-30

Start date

2013-04-30

Completion date

2014-10-31

Last updated

2013-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Immunodeficiency Virus Infection

Keywords

amdoxovir, zidovudine, HIV, HAART, antiretroviral

Brief summary

This study is an open-label extension of RFSP-AMDX-2010 study for those subjects who received treatment with amdoxovir (300 mg or 500 mg twice daily) for 12 weeks and benefited from it. This study will examine the safety and efficacy of the investigational HIV drug, amdoxovir (300 mg and 500 mg bid doses; N = up to 30) in combination with zidovudine and lopinavir/ritonavir for 36 weeks. Subjects will continue to receive either amdoxovir 300 mg twice daily or amdoxovir 500 mg twice daily, each in combination with zidovudine 300 mg twice daily and lopinavir/ritonavir (400 mg/100 mg twice daily) for additional 36 weeks.

Interventions

DRUGamdoxovir 300 mg bid

2 x 150 mg capsules bid

DRUGamdoxovir 500 mg bid

2 x 250 mg capsules bid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have completed Study RFSP-AMDX-2010 and received treatment with amdoxovir (500 mg bid or 300 mg bid) for 12 weeks before entry into study RFSP-AMDX-2012. * Must have maintained ≥ 1.0 log10 copies/mL from baseline at Week 12 in Study RFSP-AMDX-2010. * Must not have had any serious adverse experience since enrollment in Study RFSP-AMDX-2010, whether or not considered to be study drug-related.

Exclusion criteria

* Subjects who require ongoing therapy of nephrotoxic drugs or competitors of renal excretion. * Subjects who require therapy with hematologic, bone marrow suppressive or cytotoxic agents. * Subjects who require medications that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with life-threatening adverse events. * Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulations. * Women who are pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame
HIV-1 viral load	up to 48 Weeks

Secondary

Measure	Time frame
Incidence of adverse events	up to 48 Weeks
Changes in Immunologic Function (CD4 cell counts)	from baseline to Weeks 18, 24, 30, 36, 42, 48

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026